Text Size

Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00687492
First received: May 28, 2008
Last updated: December 1, 2010
Last verified: December 2010
History of Changes
  Purpose

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.


Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
  • The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
  • The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Estimated Enrollment: 8000
Study Start Date: May 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Criteria

Inclusion Criteria:

  • 2 or more risk factors (according to NCEP ATP III guideline)
  • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in a clinical study during the last 90 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00687492

  Show 59 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Park Jeong Euy Sungkyunkwan University School of Medicine
  More Information

No publications provided

Responsible Party: Joher Raniwalla, AstraZeneca
ClinicalTrials.gov Identifier: NCT00687492     History of Changes
Other Study ID Numbers: NIS-CAP-DUM-2008/1
Study First Received: May 28, 2008
Last Updated: December 1, 2010
Health Authority: Philippines: Bureau of Food and Drugs

Keywords provided by AstraZeneca:
hypercholesterolemia
NCEP ATP III guidelines
survey

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 19, 2013